Main description:

This book, in two volumes, focuses on contemporary issues and dilemmas in relation to depression. The aim is to equip readers with an up-to-date understanding of the clinical and neurobiological underpinnings of depression and their relation to clinical manifestations and the development of more effective treatments. This first volume is devoted specifically to biomedical and neurobiological issues. Detailed information is presented on a wide range of topics, including genetics, molecular and cellular biology, and aspects at the neural circuit and multicellular system levels. Readers will gain a deeper appreciation of the factors and interactions underlying individual variation in responsiveness to stress and vulnerability to depression, as well as a clear understanding of potential treatment targets and causes of treatment resistance based on the latest research. A concluding section considers progress towards precision psychiatry and gender and cultural differences in depression. The companion volume is dedicated to clinical and management issues in depression. Understanding Depression will be an excellent source of information for both researchers and practitioners in the field.

Contents:

1.Genetic and epigenetic aspects of depression.- 1-1.Highlights on pharmacogenetics and pharmacogenomics in depression.- 1-2.Imaging genetics studies on susceptibility genes for major depressive disorder: the present and the future.- 1-3.Gene-environmental interaction and role of epigenetic in depression.- 1-4.The role of microRNAs and long noncoding RNAs in depression: diagnosis and therapeutic implication.- 1-5.The role of early life stress in HPA axis and depression.- 2.Molecular-, cellular-level aspects of depression.- 2-1.Complex role of serotonin receptors in depression.- 2-2.Emerging role of glutamate receptors in pathophysiology of depression.- 2-3.New perspective on mTOR pathways: a new target of depression.- 2-4.Cellular aging in depression: the role of telomere-telomerase system.- 2-5.Differentiation and biological markers in subtype of depression.- 3.Neural circuit-level aspect of depression.- 3-1.Molecular, structural, and functional neuroimaging in depression.- 3-2.Resting-state activity in depression; a link to spatiotemporal psychopathology.- 3-3.Functional neuroimaging in depression: a tool to predict treatment outcome and response.- 3-4.Cortical-subcortical interactions in the pathophysiology of depression.- 3-5.Pathophysiology and treatment strategies for different types of depression.- 3-6.The effect of neurostimulation in depression.- 4.Multicellular system-level aspect of depression.- 4-1.Inflammation, depression and neurodegeneration: a possible cause of dementia in late life depression?.- 4-2.Gut-microbiota-brain axis and depression.- 4-3.The interactions of immune inflammation and oxidative and nitrosative stress with the kynurenine and melatonergic pathways in depression.- 4-4.Glia-neuron cross-talk in depression.- 4-5.Depression model in primate: relevance to novel drug discovery.- 5.Species-, individual-, gender-, culture-specific aspects of depression.- 5-1.Precision psychiatry: personalized clinical approach to depression.- 5-2.Gender differences in depression.- 5-3.An up-date on the epidemiology of major depressive disorder across cultures.